Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis
[摘要]
[发布日期] [发布机构]
[效力级别] [学科分类] 卫生学
[关键词] [时效性]
